BACKGROUND: The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status. METHODS: Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6. RESULTS: The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible. CONCLUSION: This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3-4.
BACKGROUND: The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status. METHODS: Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6. RESULTS: The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible. CONCLUSION: This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLCpatients who are older than 60 years including those with a poor PS 3-4.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: P Kosmidis; N Mylonakis; D Skarlos; E Samantas; M Dimopoulos; C Papadimitriou; C Kalophonos; N Pavlidis; C Nikolaidis; C Papaconstantinou; G Fountzilas Journal: Ann Oncol Date: 2000-07 Impact factor: 32.976
Authors: T P Miller; T T Chen; C A Coltman; R M O'Bryan; R B Vance; G B Weiss; W S Fletcher; R L Stephens; R B Livingston Journal: J Clin Oncol Date: 1986-04 Impact factor: 44.544
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Hai Rim Shin; Yoon Ok Ahn; Jong Myon Bae; Myung Hee Shin; Duk Hee Lee; Choong Won Lee; Hee Choul Ohrr; Don Hee Ahn; Jacques Ferlay; Dornald Maxwell Parkin; Dae Kyu Oh; Jae Gahb Park Journal: Cancer Res Treat Date: 2002-12 Impact factor: 4.679
Authors: J Klastersky; J P Sculier; G Bureau; P Libert; P Ravez; G Vandermoten; J Thiriaux; J Lecomte; R Cordier; G Dabouis Journal: J Clin Oncol Date: 1989-08 Impact factor: 44.544
Authors: P D Bonomi; D M Finkelstein; J C Ruckdeschel; R H Blum; M D Green; B Mason; R Hahn; D C Tormey; J Harris; R Comis Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: T Le Chevalier; D Brisgand; J Y Douillard; J L Pujol; V Alberola; A Monnier; A Riviere; P Lianes; P Chomy; S Cigolari Journal: J Clin Oncol Date: 1994-02 Impact factor: 44.544